Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study

Marta Kalousová, Tomáš Krechler, Marie Jáchymová, Aleš A. Kuběna, Aleš Žák, Tomáš Zima

. 2012 ; 33 (5) : 1695-1700.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13000620

Grantová podpora
NS9769 MZ0 CEP - Centrální evidence projektů

Prognosis of patients with pancreas cancer is very poor. The aim of the study was to test the significance of laboratory parameters in the prognosis of patients with pancreas cancer. The studied group included 57 patients (31 men, 26 women, mean age 65 ± 9 years). Blood was collected at the time of diagnosis of pancreas cancer and basic laboratory parameters, including nutritional and inflammatory markers and tumour markers were measured. Patients were followed up until death (median survival 147 days). Ferritin, iron, albumin, prealbumin, cholinesterase, haemoglobin, C-reactive protein, alkaline phosphatase and carcinoembryonic antigen were significant for patients' prognosis in univariate analysis while CA 19-9, bilirubin, liver, pancreas and kidney tests and lipids were not. Multivariate Cox regression demonstrated ferritin, iron and albumin as independent mortality predictors (RR (95%CI), per standard deviation: ferritin 1.497(1.215-2.241), p = 0.002; albumin, 0.716(0.521-0.977), p = 0.035; iron, 0.678(0.504-0.915), p = 0.010). Iron correlated significantly with albumin (r = 0.397, p = 0.002) but neither iron nor albumin correlated with ferritin. Patients who survived 100 days had significantly lower ferritin (median 239 μg/l vs. non-survivors 435 μg/l, p = 0.014), significantly higher albumin but the difference in serum iron was not quite significant. ROC analysis for ferritin revealed AUC for 100 days survival of 0.710, p = 0.007 (and 0.725, p = 0.004 for 200 days survival). AUC for albumin for 100 days survival was not significant (p = 0.073). This study points out ferritin as an independent mortality predictor in patients with pancreas cancer. High serum levels of ferritin at the time of diagnosis of pancreas cancer indicate bad prognosis of the patient.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13000620
003      
CZ-PrNML
005      
20170411113321.0
007      
ta
008      
130108s2012 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13277-012-0426-z $2 doi
035    __
$a (PubMed)22875781
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kalousová, Marta $u Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. marta.kalousova@seznam.cz
245    10
$a Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study / $c Marta Kalousová, Tomáš Krechler, Marie Jáchymová, Aleš A. Kuběna, Aleš Žák, Tomáš Zima
520    9_
$a Prognosis of patients with pancreas cancer is very poor. The aim of the study was to test the significance of laboratory parameters in the prognosis of patients with pancreas cancer. The studied group included 57 patients (31 men, 26 women, mean age 65 ± 9 years). Blood was collected at the time of diagnosis of pancreas cancer and basic laboratory parameters, including nutritional and inflammatory markers and tumour markers were measured. Patients were followed up until death (median survival 147 days). Ferritin, iron, albumin, prealbumin, cholinesterase, haemoglobin, C-reactive protein, alkaline phosphatase and carcinoembryonic antigen were significant for patients' prognosis in univariate analysis while CA 19-9, bilirubin, liver, pancreas and kidney tests and lipids were not. Multivariate Cox regression demonstrated ferritin, iron and albumin as independent mortality predictors (RR (95%CI), per standard deviation: ferritin 1.497(1.215-2.241), p = 0.002; albumin, 0.716(0.521-0.977), p = 0.035; iron, 0.678(0.504-0.915), p = 0.010). Iron correlated significantly with albumin (r = 0.397, p = 0.002) but neither iron nor albumin correlated with ferritin. Patients who survived 100 days had significantly lower ferritin (median 239 μg/l vs. non-survivors 435 μg/l, p = 0.014), significantly higher albumin but the difference in serum iron was not quite significant. ROC analysis for ferritin revealed AUC for 100 days survival of 0.710, p = 0.007 (and 0.725, p = 0.004 for 200 days survival). AUC for albumin for 100 days survival was not significant (p = 0.073). This study points out ferritin as an independent mortality predictor in patients with pancreas cancer. High serum levels of ferritin at the time of diagnosis of pancreas cancer indicate bad prognosis of the patient.
650    _2
$a ferritiny $x krev $7 D005293
650    _2
$a lidé $7 D006801
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory slinivky břišní $x krev $x mortalita $x patologie $7 D010190
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prognóza $7 D011379
650    _2
$a ROC křivka $7 D012372
650    _2
$a nádorové biomarkery $x krev $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krechler, Tomáš $u 4th Department of Medicine - Department of Gastroenterology and Hepatology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Jáchymová, Marie $u Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Kuběna, Aleš A. $u Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Žák, Aleš $u 4th Department of Medicine - Department of Gastroenterology and Hepatology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Zima, Tomáš $u Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
773    0_
$w MED00008757 $t Tumour biology the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 33, č. 5 (2012), s. 1695-1700
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22875781 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130108 $b ABA008
991    __
$a 20170411113620 $b ABA008
999    __
$a ok $b bmc $g 963402 $s 798784
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 33 $c 5 $d 1695-1700 $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
GRA    __
$a NS9769 $p MZ0
LZP    __
$a Pubmed-20130108

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...